48
Participants
Start Date
December 18, 2017
Primary Completion Date
April 15, 2018
Study Completion Date
April 15, 2018
Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
Dexcom CGM G5
"The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes"
Continuous Subcutaneous Insulin Infusion
Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.
University of Virginia Center for Diabetes Technology, Charlottesville
Barbara Davis Center, University of Colorado, Aurora
Stanford University, Stanford
Tandem Diabetes Care, Inc.
INDUSTRY
DexCom, Inc.
INDUSTRY
University of Virginia
OTHER